title: Attenuating effects of coenzyme Q10 and amlodipine in ulcerative colitis model in rats.
abstract: BACKGROUND
  Ulcerative colitis is a chronic inflammatory bowel disease. Recent studies reported a pivotal role of elevated intracellular calcium in this disorder. Coenzyme Q10 (CoQ10) and amlodipine are known to maintain cellular energy, decrease intracellular calcium concentration in addition to their antioxidant and anti-inflammatory properties.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the possible protective effects of CoQ10, amlodipine and their combination on ulcerative colitis.
  
  
  METHODS
  Colitis was induced in rats by intracolonic injection of 3% acetic acid. CoQ10 (10 mg/kg), amlodipine (3 mg/kg) and their combination were administered for 8 consecutive days before induction of colitis.
  
  
  RESULTS
  Our results showed that administration of CoQ10, amlodipine and their combination decreased colon tissue malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), prostaglandin E2 (PGE2), myeloperoxidase (MPO) and heat shock protein (HSP70) levels induced by intracolonic injection of acetic acid and restored many of the colon structure in histological examination. On the other hand, they increased superoxide dismutase (SOD) activity, adenosine-5'-triphosphate (ATP) and interleukin-10 (IL-10) colonic contents.
  
  
  CONCLUSIONS
  Administration of either CoQ10 or amlodipine was found to protect against acetic acid-induced colitis. Moreover, their combination was more effective than individual administration of either of them. The protective effect of CoQ10 and amlodipine may be in part via their antioxidant, anti-inflammatory and energy restoration properties.
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University , Ein Helwan, Cairo , Egypt and.
authors.forename: Engy M
authors.initials: EM
authors.lastname: El Morsy
authors.forename: Rehab
authors.initials: R
authors.lastname: Kamel
authors.forename: Maha A E
authors.initials: MA
authors.lastname: Ahmed
mesh_terms: D017311:Amlodipine / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003106:Colon / Q000276:immunology* / Q000473:pathology; D015232:Dinoprostone / Q000276:immunology; D004195:Disease Models, Animal; D004734:Energy Metabolism / Q000187:drug effects* / Q000276:immunology; D053583:Interleukin-1beta / Q000276:immunology; D008297:Male; D008315:Malondialdehyde / Q000276:immunology; D009195:Peroxidase / Q000276:immunology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; C000594089:IL1B protein, rat; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; D014451:Ubiquinone; D017311:Amlodipine; D008315:Malondialdehyde; D009195:Peroxidase; C024989:coenzyme Q10; D015232:Dinoprostone
keywords: Amlodipine; CoQ10; inflammation; oxidative stress; ulcerative colitis